Metronomic chemotherapy: Possible clinical application in advanced hepatocellular carcinoma

Translational Oncology

Volumn 6, Issue 5, 2013, Pages 511-519

  Torimura, Takuji ^a   Iwamoto, Hideki ^a   Nakamura, Toru ^a   Koga, Hironori ^a   Ueno, Takato ^a   Kerbel, Robert S ^b   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANTHRACYCLINE; BEVACIZUMAB; BRIVANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; INTERFERON; IRINOTECAN; LINIFANIB; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY DC101; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; SORAFENIB; TAMOXIFEN; TEMOZOLOMIDE; TRASTUZUMAB; UFT; UNINDEXED DRUG; VANDETANIB; VINBLASTINE;

ADVANCED CANCER; ANGIOGENESIS; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; CYTOTOXICITY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; FATIGUE; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LOW DRUG DOSE; METRONOMIC DRUG ADMINISTRATION; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; UPREGULATION; VOMITING;

EID: 84885788040     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13481     Document Type: Article

References (141)

1. Bruix J (2008). Liver cancer: an evolving challenge reaching research maturity. Hepatology 47, 1103-1104.
2. Kerbel RS and Kamen BA (2004). The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4, 423-436.
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, and Johnson DH (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346, 92-98.
4. Nieto Y (2003). The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer. Haematologica 88, 201-211.
5. Roche H, Viens P, Biron P, Lotz JP, and Asselain B (2003). High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 10, 42-47.
6. Kim JJ and Tannock IF (2005). Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5, 516-525.
7. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186.
8. Folkman J (1990). What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82, 4-6.
9. Fidler IJ and Ellis LM (1994). The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79, 185-188.
10. Pahernik S, Harris AG, Schmitt-Sody M, Krasnici S, Goetz AE, Dellian M, and Messmer K (2002). Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study. Br J Cancer 86, 1622-1627.
11. Judy BF, Aliperti LA, Predina JD, Levine D, Kapoor V, Thorpe PE, Albelda SM, and Singhal S (2012). Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery. Neoplasia 14, 352-359.
12. Kerbel RS (1991). Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13, 31-36.
13. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, and Kerbel RS (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105, R15-R24.
14. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS, and Folkman J (2000). Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60, 1878-1886.
15. Hanahan D, Bergers G, and Bergsland E (2000). Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105, 1045-1047.
16. Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, and Kerbel RS (2005). Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106, 3058-3061.
17. Pasquier E, Kieran MW, Sterba J, Shaked Y, Baruchel S, Oberlin O, Kivivuori MS, Peyrl A, Diawarra M, Casanova M, et al. (2011). Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. Trans Oncol 4, 203-211.
18. Swaminathan R, Lucas E, and Sankaranarayanan R (2011). Cancer survival in Africa, Asia, the Caribbean and Central America: database and attributes. IARC Sci Publ 162, 23-31.
19. André N, Banavali S, Snihur Y, and Pasquier E (2013). Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol 14, e239-e248.
20. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D (2011). Global cancer statistics. CA Cancer J Clin 61, 69-90.
21. Parkin DM, Bray F, Ferlay J, and Pisani P (2001). Estimating the world cancer burden: Globocan 2000. Int J Cancer 94, 153-156.
22. Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Takashima T, Nakanuma Y, Unoura M, Kobayashi K, Izumi R, Ida M, et al. (1991). Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 178, 493-497.
23. Honda H, Tajima T, Kajiyama K, Kuroiwa T, Yoshimitsu K, Irie H, Aibe H, Shimada M, and Masuda K (1999). Vascular changes in hepatocellular carcinoma: correlation of radiologic and pathologic findings. AJR Am J Roentgenol 173, 1213-1217.
24. Yang ZF and Poon RT (2008). Vascular changes in hepatocellular carcinoma. Anat Rec (Hoboken) 291, 721-734.
25. Bruix J and Sherman M (2005). Management of hepatocellular carcinoma. Hepatology 42, 1208-1236.
26. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, Richardson P, and El-Serag HB (2011). Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 140, 1182-1188. e1.
27. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378-390.
28. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al. (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol 10, 25-34.
29. Nakano M, Ando E, Kuromatsu R, Torimura T, Sumie S, Takata A, Fukushima N, Kurogi J, Niizeki T, Iwamoto H, et al. (2010). Recent progress in the management of hepatocellular carcinoma detected during a surveillance program in Japan. Hepatol Res 40, 989-996.
30. Yu DQ, Lin SG, Chen JY, Xue L, Li G, Dong HJ, and Zhou YL (2011). Effect of atorvastatin therapy on borderline vulnerable lesions in patients with acute coronary syndrome. Arch Med Sci 7, 433-439.
31. Sutcliffe RP, Lewis D, Kane PA, Portmann BC, O'Grady JG, Karani JB, Rela M, and Heaton ND (2011). Manganese-enhanced MRI predicts the histological grade of hepatocellular carcinoma in potential surgical candidates. Clin Radiol 66, 237-243.
32. Lencioni R (2010). Surveillance and early diagnosis of hepatocellular carcinoma. Dig Liver Dis 42(suppl 3), S223-S227.
33. Llovet JM, Burroughs A, and Bruix J (2003). Hepatocellular carcinoma. Lancet 362, 1907-1917.
34. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, and Sata M (2002). Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 95, 588-595.
35. Nagamatsu H, Hiraki M, Mizukami N, Yoshida H, Iwamoto H, Sumie S, Torimura T, and Sata M (2010). Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Aliment Pharmacol Ther 32, 543-550.
36. Nerenstone S and Friedman M (1987). Medical treatment of hepatocellular carcinoma. Gastroenterol Clin North Am 16, 603-612.
37. Greten TF, Manns MP, and Korangy F (2008). Immunotherapy of HCC. Rev Recent Clin Trials 3, 31-39.
38. Llovet JM and Bruix J (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37, 429-442.
39. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, et al. (2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359, 1734-1739.
40. O'Neil BH and Venook AP (2007). Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. Oncologist 12, 1425-1432.
41. Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, Mok TS, Yeo W, Liew CT, Leung NW, et al. (1999). Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5, 1676-1681.
42. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, et al. (2005). A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97, 1532-1538.
43. Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, et al. (2007). Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 25, 3069-3075.
44. Castells A, Bruix J, Brú C, Ayuso C, Roca M, Boix L, Vilana R, and Rodés J (1995). Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 109, 917-922.
45. Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, and Hadziyannis SJ (1995). Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 21, 1535-1542.
46. Riestra S, Rodriguez M, Delgado M, Suárez A, Gonzalez N, de la Mata M, Diaz G, Miño-Fugarolas G, and Rodrigo L (1998). Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol 26, 200-203.
47. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, et al. (2004). Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101, 578-586.
48. Fuchs CS, Clark JW, Ryan DP, Kulke MH, Kim H, Earle CC, Vincitore M, Mayer RJ, and Stuart KE (2002). A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 94, 3186-3191.
49. Okada S, Okazaki N, Nose H, Shimada Y, Yoshimori M, and Aoki K (1993). A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 50, 22-26.
50. Stuart K, Tessitore J, and Huberman M (1996). 5-Fluorouracil and alphainterferonin hepatocellular carcinoma. Am J Clin Oncol 19, 136-139.
51. Tetef M, Doroshow J, Akman S, Coluzzi P, Leong L, Margolin K, Morgan RJ Jr, Raschko J, Shibata S, Somlo G, et al. (1995). 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest 13, 460-463.
52. Davis RB, Van Echo DA, Leone LA, and Henderson ES (1986). Phase II trial of mitoxantrone in advanced primary liver cancer: a Cancer and Leukemia Group B Study. Cancer Treat Rep 70, 1125-1126.
53. Shiu W, Mok SD, Leung N, Li M, Zacharia A, Li A, and Martin C (1987). Phase 2 study of high dose etoposide (VP16-213) in hepatocellular carcinoma. Jpn J Clin Oncol 17, 113-115.
54. Yoshino M, Okazaki N, Yoshida T, Kanda Y, Miki M, Oda H, Sasagawa Y, Hayashi S, and Hashimoto N (1989). A phase II study of etoposide in patients with hepatocellular carcinoma by the Tokyo Liver Cancer Chemotherapy Study Group. Jpn J Clin Oncol 19, 120-122.
55. Harvey WH, Fleming TR, Von Hoff DD, Katterhagen JG, and Coltman CA Jr (1987). Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group Study. Cancer Treat Rep 71, 1319-1320.
56. Burroughs A, Hochhauser D, and Meyer T (2004). Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 5, 409-418.
57. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64, 7099-7109.
58. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, et al. (2005). Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23, 965-972.
59. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, and Santoro M (2006). BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98, 326-334.
60. Forner A, Reig ME, de Lope CR, and Bruix J (2010). Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30, 61-74.
61. Villanueva A and Llovet JM (2011). Targeted therapies for hepatocellular carcinoma. Gastroenterology 140, 1410-1426.
62. Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, and Kerbel RS (2006). Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 66, 3386-3391.
63. Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R, and Kerbel RS (2010). Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 9, 996-1006.
64. Ghiringhelli F, Manckoundia P, and Pfitzenmeyer P (2004). Acute tubulointerstitial nephritis due to Salmonella typhimurium infection. Eur J Intern Med 15, 401.
65. Loeffler M, Krüger JA, and Reisfeld RA (2005). Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res 65, 5027-5030.
66. +T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105, 2862-2868.
67. Martin-Padura I, Marighetti P, Agliano A, Colombo F, Larzabal L, Redrado M, Bleau AM, Prior C, Bertolini F, and Calvo A (2012). Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Invest 92, 952-966.
68. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, and Kerbel RS (2007). Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67, 3560-3564.
69. Ma J, Chen CS, Blute T, and Waxman DJ (2011). Antiangiogenesis enhances intratumoral drug retention. Cancer Res 71, 2675-2685.
70. Vacca A, Ribatti D, Iurlaro M, Merchionne F, Nico B, Ria R, and Dammacco F (2002). Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res 11, 103-118.
71. Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, and Braguer D (2005). Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 65, 2433-2440.
72. Chen YM, Fan WC, Tsai CM, Liu SH, Shih JF, Chou TY, Wu CH, Chou KT, Lee YC, Perng RP, et al. (2011). A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. J Thorac Oncol 6, 1110-1116.
73. Ooyama A, Oka T, Zhao HY, Yamamoto M, Akiyama S, and Fukushima M (2008). Anti-angiogenic effect of 5-fluorouracil-based drugs against human colon cancer xenografts. Cancer Lett 267, 26-36.
74. Kubisch R, Meissner L, Krebs S, Blum H, Gunther M, Roidl A, and Wagner E (2013). A comprehensive gene expression analysis of resistance formation upon metronomic cyclophosphamide therapy. Trans Oncol 6, 1-9.
75. Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, and Kerbel RS (2011). Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 13, 40-48.
76. Hirata S, Matsubara T, Saura R, Tateishi H, and Hirohata K (1989). Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 32, 1065-1073.
77. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, and Taraboletti G (1996). The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2, 1843-1849.
78. Bocci G, Nicolaou KC, and Kerbel RS (2002). Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62, 6938-6943.
79. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A, and Dammacco F (1999). Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94, 4143-4155.
80. Wang J, Lou P, Lesniewski R, and Henkin J (2003). Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14, 13-19.
81. Grant DS, Williams TL, Zahaczewsky M, and Dicker AP (2003). Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 104, 121-129.
82. Nyberg P, Xie L, and Kalluri R (2005). Endogenous inhibitors of angiogenesis. Cancer Res 65, 3967-3979.
83. Bocci G, Francia G, Man S, Lawler J, and Kerbel RS (2003). Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100, 12917-12922.
84. Bocci G, Fioravanti A, Orlandi P, Di Desidero T, Natale G, Fanelli G, Viacava P, Naccarato AG, Francia G, and Danesi R (2012). Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1. Neoplasia 14, 833-845.
85. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, and Kalluri R (2004). Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64, 1570-1574.
86. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, and Bouck NP (1997). CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138, 707-717.
87. Guo N, Krutzsch HC, Inman JK, and Roberts DD (1997). Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57, 1735-1742.
88. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, and Bouck N (2000). Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6, 41-48.
89. Gupta K, Gupta P, Wild R, Ramakrishnan S, and Hebbel RP (1999). Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 3, 147-158.
90. Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, et al. (2009). Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 8, 1867-1877.
91. Lee K, Qian DZ, Rey S, Wei H, Liu JO, and Semenza GL (2009). Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumorinduced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 106, 2353-2358.
92. Takahashi H and Shibuya M (2005). The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109, 227-241.
93. Ferrara N, Gerber HP, and LeCouter J (2003). The biology of VEGF and its receptors. Nat Med 9, 669-676.
94. Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nolè F, et al. (2006). Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 17, 232-238.
95. Correale P, Cerretani D, Remondo C, Martellucci I, Marsili S, La Placa M, Sciandivasci A, Paolelli L, Pascucci A, Rossi M, et al. (2006). A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep 16, 133-140.
96. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, and Isner JM (1997). Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967.
97. Isner JM and Asahara T (1999). Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 103, 1231-1236.
98. Jin H, Aiyer A, Su J, Borgstrom P, Stupack D, Friedlander M, and Varner J (2006). A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. J Clin Invest 116, 652-662.
99. Bagley RG, Weber W, Rouleau C, and Teicher BA (2005). Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy. Cancer Res 65, 9741-9750.
100. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, and Weinberg RA (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348.
101. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, and Kerbel RS (2003). Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63, 4342-4346.
102. Tanaka H, Matsushima H, Mizumoto N, and Takashima A (2009). Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells. Cancer Res 69, 6978-6986.
103. Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, Omata H, and Fujii H (2006). CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 55, 1064-1071.
104. +regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34, 336-344.
105. Banissi C, Ghiringhelli F, Chen L, and Carpentier AF (2009). Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 58, 1627-1634.
106. +regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56, 641-648.
107. Tanaka H, Matsushima H, Nishibu A, Clausen BE, and Takashima A (2009). Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res 69, 6987-6994.
108. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, and Kerbel RS (2002). Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62, 2731-2735.
109. Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, Hicklin D, and Kerbel RS (2002). Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 8, 221-232.
110. Chen CA, Ho CM, Chang MC, Sun WZ, Chen YL, Chiang YC, Syu MH, Hsieh CY, and Cheng WF (2010). Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol Ther 18, 1233-1243.
111. Tang TC, Man S, Lee CR, Xu P, and Kerbel RS (2010). Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia 12, 264-274.
112. Shen FZ, Wang J, Liang J, Mu K, Hou JY, and Wang YT (2010). Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells? Int J Exp Pathol 91, 10-16.
113. Park ST, Jang JW, Kim GD, Park JA, Hur W, Woo HY, Kim JD, Kwon JH, Yoo CR, Bae SH, et al. (2010). Beneficial effect of metronomic chemotherapy on tumor suppression and survival in a rat model of hepatocellular carcinoma with liver cirrhosis. Cancer Chemother Pharmacol 65, 1029-1037.
114. Tang TC, Man S, Xu P, Francia G, Hashimoto K, Emmenegger U, and Kerbel RS (2010). Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia 12, 928-940.
115. Zhou F, Hu J, Shao JH, Zou SB, Shen SL, and Luo ZQ (2012). Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol 138, 1879-1890.
116. Iwamoto H, Torimura T, Nakamura T, Hashimoto O, Inoue K, Kurogi J, Niizeki T, Kuwahara R, Abe M, Koga H, et al. (2011). Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. Neoplasia 13, 187-197.
117. Jang JW, Park ST, Kwon JH, You CR, Choi JY, Jung CK, Bae SH, and Yoon SK (2011). Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinoma. Exp Mol Med 43, 305-312.
118. Pasquier E, Kavallaris M, and André N (2010). Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7, 455-465.
119. Romiti A, Cox MC, Sarcina I, Di Rocco R, D'Antonio C, Barucca V, and Marchetti P (2013). Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother Pharmacol 72, 13-33.
120. Ribatti D, Nico B, Ranieri G, Specchia G, and Vacca A (2013). The role of angiogenesis in human non-Hodgkin lymphomas. Neoplasia 15, 231-238.
121. Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R, Peruzzotti G, Goldhirsch A, Pietri E, and Colleoni M (2006). Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 6, 225.
122. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, and Hamajima N (2004). A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350, 1713-1721.
123. Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K, et al. (2009). Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. J Clin Oncol 27, 1368-1374.
124. Herrlinger U, Rieger J, Steinbach JP, Nägele T, Dichgans J, and Weller M (2005). UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. J Neurooncol 71, 295-299.
125. Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, et al. (2007). Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 9, 354-363.
126. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE II, Marcello JE, Norfleet J, et al. (2009). Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 101, 1986-1994.
127. Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, et al. (2009). Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 27, 3861-3867.
128. Jurado JM, Sánchez A, Pajares B, Pérez E, Alonso L, and Alba E (2008). Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin Transl Oncol 10, 583-586.
129. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, et al. (2008). Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26, 76-82.
130. Kerbel RS (2012). Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. J Mammary Gland Biol Neoplasia 17, 229-239.
131. Treiber G, Wex T, and Malfertheiner P (2009). Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer. J Cancer Res Clin Oncol 135, 271-281.
132. Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C, and Cheng AL (2010). Phase II study of combining sorafenib with metronomic tegafur/ uracil for advanced hepatocellular carcinoma. J Hepatol 53, 126-131.
133. Hsu CY, Shen YC, Yu CW, Hsu C, Hu FC, Hsu CH, Chen BB, Wei SY, Cheng AL, and Shih TT (2011). Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J Hepatol 55, 858-865.
134. Yau T, Chan P, Ng KK, Chok SH, Cheung TT, Fan ST, and Poon RT (2009). Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 115, 428-436.
135. Woo HY, Youn JM, Bae SH, Jang JW, Cha JH, Kim HL, Chun HJ, Choi BG, Choi JY, and Yoon SK (2012). Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis. Korean J Hepatol 18, 32-40.
136. Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, and Cheng AL (2010). Early alphafetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 116, 4590-4596.
137. Shao YY, Lin ZZ, Hsu C, Lee KD, Hsiao CH, Lu YS, Huang CC, Shen YC, Hsu CH, and Cheng AL (2012). Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. Oncology 82, 59-66.
138. Shao YY, Lin ZZ, Chen TJ, Hsu C, Shen YC, Hsu CH, and Cheng AL (2011). High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy. Oncology 81, 98-103.
139. Ballardini P, Marri I, Margutti G, Aliberti C, Benea G, and Manfredini R (2010). Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma. Tumori 96, 768-770.
140. Brandi G, de Rosa F, Bolondi L, Agostini V, Di Girolamo S, Nobili E, and Biasco G (2010). Durable complete response of hepatocellular carcinoma after metronomic capecitabine. Tumori 96, 1028-1030.
141. Allegrini G, Di Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, Chericoni S, Loupakis F, Di Paolo A, Masi G, et al. (2012). Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis 15, 275-286.